The Randstad, Netherlands
Martin his experience in virology started in 1990 as researcher in HIV-1/2 basic research. In order to broaden his knowledge in the field of Virology he changed position at the Erasmus university hospital Rotterdam in 1998 to start working in the field of virus diagnostics. In 2009 he became Head of the unit Clinical Virology and was in this position responsible for finance, HRM and quality of the virus diagnostic portfolio. In January 2015 he started working full time as Director Clinical Services at Viroclinics Biosciences BV with as main responsibilities implementation and maintenance of culture, serological and molecular diagnostic assays, global clinical trial operations business development and client contacts. At the same time he also took up a part time job as assessor ISO15189 for the Dutch Board for Accreditation. By working more than 30 years in both academic and commercial virus diagnostic laboratories he has built up experience in managing an ISO15189 accredited laboratory with more than 40 co-workers and developing and implementation of diagnostic methods and implementing logistic operations for patient management and clinical trials. During that time he also weekly attended the infectious disease specialists meetings and thus acquired in depth knowledge on treatment of patients infected with a range of different viral diseases. He has been on missions to the Middle East (Syria/Lebanon/Egypt), West Africa (Cape Verde Isles/Gambia/Guinee Conakry), Brazil and Indonesia to assist WHO and local governments and laboratories in evaluating country preparedness for virus outbreaks and was amongst others involved in the global outbreak response for SARS-CoV-1; influenza H1N1pdm09 and Ebola. As consultant he has extensive experience with pre-clinical development; controlled human infection models and clinical trial management for antivirals and vaccines. He is (co-)founder of Clinical Virology And Diagnostics (his own consultancy company); CHIMagents (sold to Open Orphan LtD as of July 2021); Artemis BioServices (a CRO specialized in clinical trial diagnostics and pre-clinical services); Chimunomics (a UK based company dedicated to manufacturing human challenge agents and providing consultancy services in that field) and IQ-IDM (a start-up biotech developing new antivirals for RSV; Dengue and Rabies).
As consultant Martin offers his virological expertise in the fields of: (pre-)clinical research; global clinical trial design, operations and analyses; health authority reporting; development and implementation of new diagnostic methods; implementation of existing diagnostic methods; assessment of laboratories and quality systems.
Chief scientific officer and founder of IQ-IDM a biotech that aims to develop therapies for unmet medical needs by repurposing drugs with a known safety profile and clinical effect in men to de-risk development plans.
Outsourced through Clinical Virology And Diagnostics B.V.
As Chief Scientific Officer of Chimunomics LtD providing consultancy services in the field of human challenge trials and overseeing the production process of new and improved challenge agents. Experienced in human challenge agents production (A/Belgium/4217/2015 (H3N2); RSV and COVID-19) and running human challenge trials of both antivirals and vaccines.